# A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

> **NCT02203032** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 872 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Guselkumab
- **DRUG:** Placebo for ustekinumab
- **DRUG:** Placebo for guselkumab

## Key facts

- **NCT ID:** NCT02203032
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-07
- **Primary completion:** 2015-12-25
- **Final completion:** 2016-05-24
- **Target enrollment:** 872 (ACTUAL)
- **Last updated:** 2017-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203032, "A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02203032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*